IsoRay, Inc. (NASDAQ: ISR) IsoRay, has had an interesting week in the market thus far. After announcing that Cesium-131 was indeed effective in the treatment of cancer, the company went under attack by Adam Feuerstein; who discredited their press release and drove the stock price down. However, I’ve said a few times since then that … Read more
Hey everyone, sorry for the short break in posts this morning. Just after posting this morning’s article on MannKind, I got a call from one of our amazing readers by the name of Russel to talk about MNKD, Afrezza, and more. While the conversation first started with MannKind, we ended up talking about how many … Read more
IsoRay, Inc. (NYSEMKT: ISR) IsoRay had an interesting time in the market last week. After announcing that their Cesium-131 was as effective as current treatments; but with less time needed and less side effects, the company’s stock soared mid-week. However, the day following the press release, Adam Feuerstein attacked the company; driving the price down. … Read more
Sarepta Therapeutics (NASDAQ:SRPT) After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy … Read more
IsoRay, Inc. (NYSEMKT: ISR) This article was originally released on BioMedReports. However, I found it incredibly interesting. So, I thought I’d share. Considering the blatant attack Adam Feuerstein recently made against IsoRay and it’s Cesium-131 release, I thought it would be important to share a little bit about who Adam Feuerstein is and why ISR investors … Read more
IsoRay, Inc. (NYSEMKT: ISR) IsoRay is an incredible company that has proven to be innovative in the cancer treatment space. As a matter of fact, after releasing data with regard to the effectiveness of Cesium-131 last week, the company’s stock climbed. However, there seems to be one issue (blatantly unfounded issue I should say) that … Read more
IsoRay, Inc. (NYSEMKT: ISR) This article was originally published at Warrior Trading News! IsoRay stock had an incredible day in the market after data was released regarding Cesium-131 on Wednesday. Unfortunately however, yesterday was a bit of a different story. Yesterday, the stock plummeted following a peer review of the data by Adam Feuerstein; and … Read more
IsoRay, Inc. (NYSEMKT: ISR) IsoRay has had a very interesting time in the market this week. After releasing positive data revolving around Cesium-131, the company’s stock skyrocketed; gaining more than 100% in a single day. However, yesterday Adam Feuerstein published a peer review that essentially stated that ISR released misleading data. As a result, the … Read more
IsoRay, Inc. (NYSEMKT: ISR) IsoRay stock had an incredible day in the market yesterday; showing gains of more than 100%. However, today the story seems to have changed. Unfortunately, the trend has turned directions and the value of the stock is falling. While some investors are starting to become a bit concerned, I have to … Read more
IsoRay, Inc. (NYSEMKT: ISR) IsoRay is a clinical stage biopharmaceutical company with a strong focus on treatment of cancer who’s stock is having an incredible day in the market today. After releasing data from a study on lung cancer, the company’s stock has gone on a strong bullish path. Today, we’ll talk about the data … Read more